# Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

> **NCT01004393** · PHASE2 · COMPLETED · sponsor: **University of Vermont** · enrollment: 12 (actual)

## Conditions studied

- Neoplasms
- Constipation
- Opioid-Related Disorders

## Interventions

- **DRUG:** Methylnaltrexone bromide

## Key facts

- **NCT ID:** NCT01004393
- **Lead sponsor:** University of Vermont
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004393, "Methylnaltrexone for Opioid-induced Constipation in Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01004393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*